Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate Resistant Prostate Cancer (mCRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. 437
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)UnknownNCT03085966
What this trial is testing

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd. 30
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Active Not RecruitingNCT03732820
What this trial is testing

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 895
Not applicableLooking for participantsNCT06321679
What this trial is testing

Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone

Who this might be right for
Castration-resistant Prostate Cancer
European Institute of Oncology 40
Very early researchLooking for participantsNCT07798778
What this trial is testing

Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 18
Early research (Phase 1)Temporarily pausedNCT05425862
What this trial is testing

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 48
Testing effectiveness (Phase 2)Ended earlyNCT04556617
What this trial is testing

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Opna Bio LLC 19
Testing effectiveness (Phase 2)Looking for participantsNCT07332455
What this trial is testing

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Who this might be right for
Neoplasms, Prostate
GlaxoSmithKline 54
Testing effectiveness (Phase 2)Study completedNCT00942578
What this trial is testing

Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)UnknownNCT03700099
What this trial is testing

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Instituto do Cancer do Estado de São Paulo 30
Early research (Phase 1)Active Not RecruitingNCT06052306
What this trial is testing

Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Bayer 232
Testing effectiveness (Phase 2)Looking for participantsNCT07594106
What this trial is testing

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals 265
Large-scale testing (Phase 3)Active Not RecruitingNCT03574571
What this trial is testing

Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 732
Testing effectiveness (Phase 2)Ended earlyNCT02379390
What this trial is testing

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
Sanofi 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06827080
What this trial is testing

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, MCRPCCancer
Zhengguo Chen 15
Testing effectiveness (Phase 2)Looking for participantsNCT05168618
What this trial is testing

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
University of Utah 33
Large-scale testing (Phase 3)Active Not RecruitingNCT06551324
What this trial is testing

Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer 600
Testing effectiveness (Phase 2)Study completedNCT04862091
What this trial is testing

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd. 69
Next Page